Inventor
LARSEN BJARNE DUE
DK37 patents
⚠️ This page may combine multiple inventors who share the name “LARSEN BJARNE DUE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ZEALAND PHARMA AS
23 patentsUS7935786B2May 3, 2011
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ZEALAND PHARMA AS48 citations98
US7414107B2Aug 19, 2008
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
ZEALAND PHARMA AS57 citations98
US6528486B1Mar 4, 2003
Peptide agonists of GLP-1 activity
ZEALAND PHARMA AS303 citations96
US9580487B2Feb 28, 2017
Method of treating stomach or bowel-related disorders by administering glucagon-like-peptide-2 (GLP-2) analogues
ZEALAND PHARMA AS12 citations92
US7745403B2Jun 29, 2010
Methods of treating chemotherapy-induced diarrhea/mucositis using glucagon-like-peptide-2(GLP-2)analogues
ZEALAND PHARMA AS18 citations92
US7622496B2Nov 24, 2009
Modified lysine-mimetic compounds
ZEALAND PHARMA AS49 citations92
US7563770B2Jul 21, 2009
Glucagon-like-peptide-2 (GLP-2) analogues
ZEALAND PHARMA AS25 citations92
US7544657B2Jun 9, 2009
Stabilized Exendin-4 compounds
ZEALAND PHARMA AS67 citations92
US7348404B2Mar 25, 2008
Solid-phase peptide synthesis and agent for use in such synthesis
ZEALAND PHARMA AS41 citations92
US7250397B2Jul 31, 2007
Antiarrhythmic peptides
ZEALAND PHARMA AS35 citations91
US7585839B2Sep 8, 2009
Medical uses of intercellular communication facilitating compounds
ZEALAND PHARMA AS25 citations85
US7176282B1Feb 13, 2007
Solid-phase peptide synthesis and agent for use in such synthesis
ZEALAND PHARMA AS14 citations83
US10253078B2Apr 9, 2019
GIP agonist compounds and methods
ZEALAND PHARMA AS5 citations81
USRE45313EDec 30, 2014
Exendin variant peptides
ZEALAND PHARMA AS15 citations81
US11001619B2May 11, 2021
GIP agonist compounds and methods
ZEALAND PHARMA AS1 citations70
US11814417B2Nov 14, 2023
GIP agonist compounds and methods
ZEALAND PHARMA AS0 citations60
US8026272B2Sep 27, 2011
Modified lysine-mimetic compounds
ZEALAND PHARMA AS3 citations58
US7550425B2Jun 23, 2009
Diuretic peptide conjugates
ZEALAND PHARMA AS2 citations56
US11324799B2May 10, 2022
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
ZEALAND PHARMA AS0 citations53
US10092648B2Oct 9, 2018
Selective glucagon-like-peptide-2 (GLP-2) analogues
ZEALAND PHARMA AS1 citations51
US11130793B2Sep 28, 2021
GLP-1/GLP-2 dual agonists
ZEALAND PHARMA AS0 citations49
US7749969B2Jul 6, 2010
N- or C- terminally modified small peptides
ZEALAND PHARMA AS0 citations49
US7737113B2Jun 15, 2010
Antiarrhythmic peptides
ZEALAND PHARMA AS1 citations45
LARSEN BJARNE DUE
5 patentsUS8642727B2Feb 4, 2014
Selective glucagon-like-peptide-2 (GLP-2) analogues
LARSEN BJARNE DUE37 citations93
US8263552B2Sep 11, 2012
Glucagon-like-peptide-2 (GLP-2) analogues
LARSEN BJARNE DUE13 citations91
US8163696B2Apr 24, 2012
Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues
LARSEN BJARNE DUE16 citations91
US9125882B2Sep 8, 2015
Glucagon-like-peptide-2 (GLP-2) analogues
LARSEN BJARNE DUE10 citations83
US8431540B2Apr 30, 2013
Modified lysine-mimetic compounds
LARSEN BJARNE DUE1 citations58